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Abstract
Background: We previously developed small hybrid proteins consisting of SUMO-1 linked to an
heptapeptide fused to the Tat protein transduction domain (PTD). The heptapeptide motif was
selected from a library of random sequences to specifically bind HIV-1 regulatory proteins Tat or
Rev. These constructs, named SHP, are able to enter primary lymphocytes and some of them inhibit
HIV-1 replication. Considering these positive results and other data from the literature, we further
tested the ability of ubiquitin or SUMO-1 linked to various PTD at their N-terminus to deliver
within cells proteins or peptides fused downstream of their diglycine motif. In this system it is
expected that the intracellular ubiquitin or SUMO-1 hydrolases cleave the PTD-Ub or PTD-
SUMO-1 modules from the cargo polypeptide, thereby allowing its delivery under an unmodified
form.
Results: Several bacterial expression vectors have been constructed to produce modular proteins
containing from the N- to the C-terminus: the FLAG epitope, a cleavage site for a protease, a PTD,
human ubiquitin or SUMO-1, and either GFP or the HA epitope. Nine different PTDs were tested,
including the Tat basic domain, wild type or with various mutations, and stretches of arginine or
lysine. It was observed that some of these PTDs, mainly the Tat PTD and seven or nine residues
long polyarginine motifs, caused association of the hybrid proteins with cells, but none of these
constructs were delivered to the cytosol. This conclusion was derived from biochemical and
immunofluorescence studies, and also from the fact that free cargo protein resulting from cleavage
by proteases after ubiquitin or SUMO-1 was never observed. However, in agreement with our
previous observations, mutation of the diglycine motif into alanine-arginine, as in the SHP
constructs, allows cytosol entry demonstrated by immunofluorescence observations on living cells
and by cell fractionation analyses. This process results from a non-endocytic pathway.
Conclusion: Our observations indicate that fusion of SUMO-1 to a peptide-PTD module allows
generation of a stable hybrid protein that is easily produced in bacteria and which efficiently enters
into cells but this property necessitates mutation of the diglycine motif at the end of SUMO-1,
thereby impairing delivery of the peptide alone.
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Background
The rapid progress in the understanding of protein net-
works underlying biological functions, as well as of the
specific roles played by particular polypeptides in human
pathologies such as cancer, has fuelled the search for
means to deliver peptides or proteins into cells within a
therapeutic perspective. Exciting developments originated
from previous studies on the viral transactivator Tat, as
well as the antennapedia transcription factor [1-3]. Char-
acterization of the capacity of these proteins to enter cells
led to the mapping of peptidic domains of limited size
responsible for this property which turned out to be trans-
ferable by linkage to various peptides or proteins [4-6]; for
a recent review see [7]). These so-called protein transduc-
tion domains (PTD) or cell-penetrating peptides raised
the possibility of delivering an exogenous protein compo-
nent into cells. This has been established for many differ-
ent proteins or peptides ex vivo and has also been shown
to work in the whole animal [8]. However, several recent
studies have raised doubts concerning the veritable capac-
ity of such hybrid proteins to enter cells [7,9-12]. For
immunofluorescence studies in particular, the fixation
step has been shown to cause possible artefacts. In some
cases reported cellular entry is therefore questionable, but
in others the observed biological effects are difficult to
explain without authentic cellular delivery [13-15]. The
exact molecular mechanism that allows penetration
within cells is also confusing. This property has been
shown in some instances to be independent of energy
consumption but in others to involve various forms of
endocytosis [7,12,16-19]. A detailed study with a hybrid
TAT-CRE construct has shown that cellular entry was
achieved through macropinocytosis [15]. From the pub-
lished data it appears that the exact mechanism involved
depends on the precise nature of the protein and of the
PTD. The cell type is also probably important.
A potential problem with peptides or proteins to be deliv-
ered into cells is their instability. Association with a folded
stable domain can increase this stability. Ubiquitin or
members of this protein family can be interesting in this
perspective. Several expression systems in bacteria or
eukaryotes have benefited from this property favouring
the production of otherwise poorly-expressed proteins
[20-24]. Indeed, fusion of ubiquitin to their N-terminus
can allow the production of such proteins. This is also the
case with SUMO-1. In addition, association with ubiqui-
tin or SUMO-1 allows easy cleavage after the diglycine
motif which terminates the protein. This possibility has
been used in particular for the experimental system which
allowed characterization of the N-end rule which states
that the stability of a protein depends on the nature of its
amino-terminal residue [25].
Considering these notions, we designed a system to
deliver proteins into cells without any addition by creat-
ing fusions with PTD-ubiquitin or PTD-SUMO-1 hybrids.
Although the system allows efficient expression in bacte-
ria and easy purification, it appeared that these hybrid
proteins do not allow efficient delivery into cells. By con-
trast, mutation of the diglycine motif and association with
a peptide motif linked to the Tat or poly arginine PTD per-
mits efficient entry and the mechanism sustaining this
entry is energy-independent.
Results and discussion
Design of fusion proteins with the capability of delivering 
a given protein
Association of various motifs with a peptide or protein
has been shown to trigger cell entry from the extracellular
milieu. Well-characterized examples of such motifs are the
Tat basic domain, stretches of arginine, and part of the
antennapedia transcription factor [4-6,26]. However,
these protein motifs are generally covalently linked to the
peptide or protein to be delivered, and hence remain asso-
ciated with it permanently, thereby potentially altering
their properties. In particular the Tat basic domain or pol-
yarginine motif confers intranuclear localisation or asso-
ciation with nucleic acids, a feature which might not be
wanted. To avoid this, we tested a system which associates
the protein with a module composed of the FLAG epitope,
a PTD and either ubiquitin or SUMO-1 (Figure 1a). The
diglycine motif of these small proteins is directly linked to
the first amino acid of the protein to be delivered, which
in our constructions was GFP, taken as a model polypep-
tide. It was anticipated that within cells ubiquitin or
SUMO-1 proteases would cleave the fusion protein after
the diglycine motif, thereby releasing GFP starting at the
first amino acid. This is known to occur in particular for
the ubiquitin ribosomal protein fusions encoded by sev-
eral cellular genes [27]. The constructs were designed to
allow easy insertion of various PTDs after the FLAG
epitope (Figure 1a). These two elements were separated by
a cleavage site for the Prescission protease, thereby allow-
ing removal of the FLAG epitope if necessary. The effi-
ciency of nine different PTDs was tested using these
constructs (Figure 1b). PTD 1 corresponds to the HIV-1
TAT basic domain. PTD 2 was defined by Ho et al. (2001)
as an efficient derivative of the former. These authors pro-
posed that strengthening of the α-helical structure of the
motif reinforces its transduction properties [28]. With the
idea of introducing these modifications in ubiquitin itself
at a later stage, PTD 3, 4 and 6 were designed from the α-
helix present in the ubiquitin fold with the aim of increas-
ing its α-helical nature, as well as its content in basic resi-
dues to confer transduction properties. PTD 5, 7 and 8 are
stretches of 9, 7 and 11 arginines, respectively. Finally,
PTD 9 corresponds to a stretch of 9 lysines.BMC Biotechnology 2008, 8:24 http://www.biomedcentral.com/1472-6750/8/24
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To examine the efficiency of these various PTDs, the ubiq-
uitin-GFP fusions were expressed in bacteria and affinity-
purified using anti-FLAG beads. All these proteins were
produced in large amounts and easily purified (A-L Vitte,
data not shown). These proteins were then incubated with
Jurkat cells which were lysed in SDS buffer and analyzed
by immunoblot using an antibody to GFP. As controls,
aliquots of purified protein and cell supernatant were also
analyzed. With purified proteins a certain amount of
cleavage occurred between Ub and GFP and bands were
seen both at the position of the complete fusion protein
and of GFP (Figure 2a, lanes 1, 4, 7 and 10). Depending
on the various PTDs, proteins were observed or not in the
cell extracts. This was clearly the case for PTD 1 and 5 (Fig-
ure 2a, lanes 6 and 9) and less efficiently for PTDs 6 and
3 (Figure 2a, lane 12 and Figure 2b, lane 4). PTDs 2 and 4
were inactive in this assay (Figure 2b, lanes 3 and 5). The
protein was also absent in the cell extract when it did not
include a PTD (Figure 2a, lane 3 and Figure 2b, lane 1).
Unexpectedly, with active PTDs only the complete fusion
protein was observed and no signal was detected at the
position of GFP alone (Figure 2a, lanes 6 and 9).
We next tested the efficiency of these PTDs in primary
lymphocytes. This was done with the ubiquitin and
SUMO-1 GFP fusion proteins bearing the Tat and polyR
PTDs. These proteins were detected in lymphocytes lysed
in SDS and this association was clearly reinforced when
lymphocytes were activated (Figure 2c, compare upper
and lower panels). The efficiency of the various PTDs was
also tested without the presence of ubiquitin or SUMO-1.
In the FPG constructs the PTD is directly upstream of the
GFP protein. Similarly to what was observed with the
ubiquitin fusion proteins, PTDs 1 and 5 mediated associ-
ation of GFP with cells (Figure 2d, lanes 1 and 2). PTD 6
was weakly active compared to the Tat and polyR motifs
(Figure 2d, lane 3). Interestingly, PTD 7 which corre-
sponds to a stretch of seven arginines was as active as PTD
5 which has nine arginines (Figure 2d, compare lanes 4
and 2), but by contrast PTD 8 with eleven arginines
showed no activity (Figure 2e, lane 3). A weak cell associ-
ation was also detected with PTD 9 which corresponds to
nine lysines (Figure 2e, lane 4).
Taken together these results show that the Tat and polyR7
or polyR9 were the most efficient motifs under these con-
ditions. In agreement with previous observations, the
polyR motif efficiency requires an optimum size of seven
to nine residues and increasing this length leads to loss of
the effect [26].
Ubiquitin and SUMO-1 fusion proteins do not enter cells
Previous observations were carried out lysing cells directly
in SDS. Unexpectedly, when lysis was performed in RIPA
buffer, these fusion proteins were not detected. Indeed,
comparative analysis of both types of extracts clearly
showed that fusion proteins with the Tat or polyR PTDs
were detected in SDS extracts but not in RIPA lysates (Fig-
ure 3a, upper panel). By contrast, equal amounts of β-
actin were detected in both extracts (Figure 3a, lower
panel). This was true for both ubiquitin and SUMO-1
fusion proteins. This suggests that these proteins are likely
to remain with the cellular debris removed by centrifuga-
Fusion proteins associating GFP with various protein trans- duction domains and either ubiquitin or SUMO-1 Figure 1
Fusion proteins associating GFP with various protein 
transduction domains and either ubiquitin or SUMO-
1.(a) Schematic representation of the different types of 
fusion proteins. Vectors were constructed to express GFP as 
a fusion with the FLAG epitope (F) and with a protein trans-
duction domain (PTD) giving proteins FPG. For other con-
structs, ubiquitin (Ub) or SUMO-1 (SUMO) was inserted 
between the PTD and the GFP fragments, so as to allow 
delivery of GFP, through cleavage after the diglycine motif 
(GG) present within both ubiquitin and SUMO-1. (b) Differ-
ent oligonucleotides were designed and annealed, so as to 
generate 9 different possible PTDs. These sequences were 
inserted after those coding for the FLAG epitope. These 
PTDs corresponded to the basic domain of the HIV-1 Tat 
protein (PTD1), to an Ala-rich derivative (PTD2), to poly-
arginine motifs (PTD5, PTD7, PTD8) and to a polylysine 
motif (PTD9). PTD3, 4 and 6 were derived from the alpha-
helical domain present within ubiquitin.BMC Biotechnology 2008, 8:24 http://www.biomedcentral.com/1472-6750/8/24
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Association of the various GFP fusion proteins with cells Figure 2
Association of the various GFP fusion proteins with cells.(a) Jurkat cells were incubated for 1 h with 0.5 µM of FUG 
(lanes 1 to 3), FP1UG (lanes 4 to 6), FP5UG (lanes 7 to 9) and FP6UG (lanes 10 to 12). After PBS wash, cells were further 
incubated in RPMI for 4 h. Cells were then washed again with PBS and after collection by centrifugation were lysed in protein 
loading buffer. Cell extracts (C), together with aliquots of the purified protein (F) and of the first incubation supernatant (S), 
were loaded onto a SDS protein gel. Immunoblot analysis was carried out using an antibody to GFP. Positions of the signal cor-
responding to the complete fusion protein (FPG) and of a cleavage product corresponding to GFP (G) are indicated on the 
left. (b) Proteins FUG, FP1UG, FP2UG, FP3UG and FP4UG were tested as described for panel A, except that only cell 
extracts were analysed by immunoblot. (c) Activated or non-activated primary lymphocytes were incubated with 0.5 µM of 
FP1UG, FP1SG, FP5UG or FP5SG for 2 h. Cells were then washed with PBS and lysed in protein loading buffer. Immunoblot 
analysis was performed as described for panel A and the positions of the signals corresponding to FPSG and FPUG are indi-
cated on the right. (d) and (e) Activated lymphocytes were incubated for 1 h with 0.5 µM of FPG fusion proteins as indicated. 
This was also done with the FG protein which lacks a PTD motif. After incubation with the proteins, cells were washed in PBS 
and further incubated in RPMI for 4 h. After a PBS wash, cells were lysed in protein loading buffer. Immunoblot analysis was 
carried out using a mix of antibody to GFP and to β-actin. Detection of this latter protein was performed to control protein 
loading in each lane. Revelation was performed with a fluorescent secondary antibody. Positions of signals corresponding to β-
actin and FPG are indicated.BMC Biotechnology 2008, 8:24 http://www.biomedcentral.com/1472-6750/8/24
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(a) Activated lymphocytes were incubated for 4 h with 0.5 µM of FP6UG (lanes 1 and 3), FP7UG (lanes 2 and 4), FP6SG (lanes  5 and 7), FP7SG (lanes 6 and 8) Figure 3
(a) Activated lymphocytes were incubated for 4 h with 0.5 µM of FP6UG (lanes 1 and 3), FP7UG (lanes 2 and 
4), FP6SG (lanes 5 and 7), FP7SG (lanes 6 and 8). After a PBS wash, cells were lysed either in protein loading buffer 
(SDS, lanes 3, 4, 7 and 8) or in RIPA buffer (RIPA, lanes 1, 2, 5 and 6). Immunoblot analysis of these extracts was performed 
with the antibody to GFP (upper panel) or to β-actin (lower panel). Signals corresponding to FPUG (U), FPSG (S) and β-actin 
are indicated on the right. (b) HeLa cells were transfected with 1 µg of plasmid encoding FP1UG, FP1SG, FP5UG or FP5SG. 24 
h after transfection, cells were washed with PBS and lysed with RIPA buffer. Samples were loaded onto a 12%-SDS protein gel 
and an immunoblot was carried out using the antibody to GFP. The position of the signal corresponding to GFP (G) is indi-
cated on the right. (c) Activated lymphocytes were incubated for 2 h with 2 µM of FP1G (top panels), FP1UG (middle panels) 
or FP1SG (bottom panels). Cells were then washed and observed by confocal microscopy. Visualisation was performed either 
with fluorescence (right panels) or with light transmission (left panels).BMC Biotechnology 2008, 8:24 http://www.biomedcentral.com/1472-6750/8/24
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tion during RIPA lysate preparation. Another intriguing
point was that complete fusion proteins were detected but
no free GFP. To examine whether this was a problem
inherent to our constructs or to absence of authentic cell
penetration, the sequences coding for the ubiquitin and
SUMO-1 GFP fusions associated with the Tat and polyR7
PTDs were cloned into a mammalian expression vector.
Cells were transfected with these vectors and then lysed in
RIPA buffer. With the ubiquitin fusion a single band was
seen at the position of GFP (Figure 3b, lanes 1 and 2).
With the SUMO-1 GFP fusion, a band was detected at the
position of GFP but another of higher molecular weight
was also seen (Figure 3b, lanes 3 and 4). This indicates
that processing of these proteins when expressed intracel-
lularly was efficient: completely for ubiquitin and par-
tially for SUMO-1. It also indicates that the resulting GFP
is stable. This observation supports the notion that when
added from the extracellular milieu these fusions do not
veritably enter cells. To analyse this further, we performed
immunofluorescence studies. Cells were incubated with
the constructs including the Tat PTD directly upstream of
GFP or upstream of the ubiquitin or SUMO-1 GFP fusion
proteins. For these three proteins only a few discontinu-
ous areas showed GFP staining and comparison with the
transmission images showed that they corresponded to
debris from dead cells (Figure 3c). Collectively these
observations were not in favour of a authentic entry of
these fusion proteins into cells. It is more likely that the
PTDs allow stable association with the cellular membrane
but not veritable delivery of the fusion protein to the
cytosol.
We then examined if this failure could be due to the size
and nature of GFP by replacing this part of the fusion pro-
teins with a small peptide. This was done by placing the
HA epitope downstream of SUMO-1 linked either to the
Tat or polyR7 PTDs (Figure 4a). Cells lysed in RIPA buffer
were analysed by HA and SUMO-1 immunoblot but this
did not reveal the presence of the fusion proteins within
cells (Figure 4b, lanes 4 to 6). As we have previously
shown that fusion proteins corresponding to SUMO-1
associated with a peptide motif together with the Tat PTD
efficiently enter cells [14], we compared these proteins
with the SUMO-1 HA fusion. As previously reported,
SHPR142 and 190 were clearly detected in the RIPA
extracts, but this was not the case with the SUMO-1 HA
construct (Figure 4c, compare lanes 1 and 2 with lanes 4
and 5). As a clear difference between both types of con-
structs was that the diglycine motif was mutated in the
SHP proteins, thereby impairing their processing, a fur-
ther study was made to determine whether this mutation
could explain the difference. It was found that restoration
of the wild type end of SUMO-1 in the SHPR190 construct
indeed leads to loss of intracellular entry (Figure. 4d and
4e).
Negative effect of the SUMO-1 diglycine motif on detection  of intracellular fusion proteins Figure 4
Negative effect of the SUMO-1 diglycine motif on 
detection of intracellular fusion proteins.(a) Schematic 
representation of fusion protein associating the FLAG-PTD-
SUMO-1 module with the HA epitope. Using FPSG vectors, 
the GFP moiety was deleted and replaced with the HA 
epitope coding sequence, giving vectors expressing FPSH 
proteins. (b) Activated lymphocytes were incubated for 2 h 
with 2 µM of the different FPSH proteins, then washed with 
PBS and lysed in RIPA buffer. Supernatant (S) or RIPA 
extracts (RE) were analysed by immunoblot using a mono-
clonal antibody to HA (c) Activated lymphocytes were incu-
bated for 2 h without (lane 3) or with 1 µM of either FP1SH 
(lane 1), FP5SH (lane 2), SHPR142 (lane 4) or SHPR190 (lane 
5). Cells were then washed with PBS and lysed with RIPA 
buffer. Cell extracts were analysed by immunoblot with mon-
oclonal antibodies to SUMO-1 (top panel) and to β-actin 
(lower panel). Signals corresponding to SUMO-1 fusion pro-
teins and to β-actin are indicated on the right. (d) Schematic 
representation of the SHP and SGHP proteins. Using the vec-
tor expressing SHPR-190, the AR motif was restored to the 
wild type GG sequence occurring at the end of SUMO-1, giv-
ing SGHP. (e) Activated lymphocytes were incubated with 
SGHP, SHPT8 or SHPR190 for 2 h and washed in PBS. RIPA 
extracts were then made and analysed by immunoblot using a 
monoclonal antibody to SUMO-1.BMC Biotechnology 2008, 8:24 http://www.biomedcentral.com/1472-6750/8/24
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Veritable cell penetration by the SHPR proteins
To strengthen the notion that the SHPR proteins indeed
enter cells, immunofluorescence analyses were performed
using living cells. The proteins were fluorescently labelled
with Alexa 488 and incubated with cells which were
washed and maintained in HBS buffer for examination by
confocal microscopy. Fluorescence was seen in many cells
and comparison with the light transmission image
showed that the fluorescent cells had a normal aspect and
did not correspond to debris of dead cells (Figure 5). Flu-
orescence was mainly seen in the nucleus. These observa-
tions are in favour of a veritable entry of SHPR within
cells. Different studies have reported controversial results
about the mechanism of cell entry mediated by PTDs [7].
This process has been reported to involve endocytosis or
not. A precise analysis conducted with a CRE-Tat PTD
fusion and a reporter gene the expression of which
depends on CRE expression, showed that macropinocyto-
sis was involved [15]. It is likely that the intervening
mechanism depends on the precise nature of the protein
or peptide associated with the PTD [12]. It is possible that
for small polypeptides, direct passage through the mem-
brane occurs, whereas for larger proteins endocytosis
takes place. To better characterize the process intervening
in the case of SHPR, we first tested whether cell entry
occurs at 4°C. Although reduced as compared to 37°C, a
clear band was seen in RIPA extracts of cells incubated at
4°C with SHPR190 (Figure 6a, lane 2, upper panel). We
then investigated if macropinocytosis could participate in
the process. To this end we tested the effect of rotenone
and amiloride. Both treatments were without effect on the
cell entry of SHPR190 (Figure 6a, compare lanes 4 and 5
with lane 3, upper panel). For unclear reasons the β-actin
signal was decreased by amiloride treatment but equal
total amounts of protein were loaded in the various lanes
(Figure 6a, lower panel). For the experiment with amilo-
ride and rotenone, cells were incubated with the protein
in HBS, not in normal medium. Under these conditions a
higher amount of protein was seen in the cell extract as
equal protein amounts were analyzed (Figure 6a, compare
lanes 1 and 3, upper panel). In agreement with previous
observations [15] this is likely due to an inhibitory effect
by the serum. We then investigated in which cell compart-
ment the protein was present. Cells incubated either with
FP1UG or SHPR190 were separated into cytoplasmic,
nuclear and membrane fractions. When the experiment
was performed with the ubiquitin fusion protein associ-
ated with the Tat PTD, the protein was seen only in the
membrane fraction and no signal was seen in the cyto-
plasmic and nuclear fractions (Figure 6b, upper panel).
Analysis of the cytoplasmic RRM2 protein indicated that
the fractionation process was correct (Figure 6b, lower
panel). By contrast, when the experiment was done with
SHPR190, the protein was mainly seen in the nuclear frac-
tion (Figure 6c, upper panel lane 2), in agreement with the
Activated lymphocytes were incubated for 2 h with 1 µM of  SHPR190 labelled with Alexa 488 Figure 5
Activated lymphocytes were incubated for 2 h with 1 
µM of SHPR190 labelled with Alexa 488. Cells were 
then washed and maintained in HBS buffer for examination 
by confocal microscopy. Visualisation was performed either 
by fluorescence (top panel) or by light transmission (bottom 
panel).BMC Biotechnology 2008, 8:24 http://www.biomedcentral.com/1472-6750/8/24
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immunofluorescence observations, and a signal was also
seen in the membrane fraction. We then tested how
reduced temperature or amiloride treatment affects com-
partmentalization of the protein. Incubation of the cells at
4°C reduced the presence of the protein in the nuclear
fraction but it was then detected in the cytoplasm, proba-
bly as a result of reduced nuclear import (Figure 6d, lanes
4 to 6). Amiloride treatment did not impair the presence
of the protein in the nucleus and even stimulated it (Fig-
ure 6d, lane 8). Interestingly, no more protein was seen in
the membrane fraction and a low amount was then seen
in the cytoplasmic fraction. Considering this effect it is
possible that amiloride treatment leads, for unclear rea-
sons, to the release of the protein fraction associated with
membranes, thereby increasing its concentration in cyto-
plasm and nucleus. These data indicate that cell entry of
the SHPR protein is energy-independent and does not
involve macropinocytosis, a process which requires func-
tional Na+/H+ exchange that is inhibited by amiloride
[15].
Taken together these observations firmly establish that
SHPR proteins are able to penetrate within cells via a
mechanism that is energy-independent. Hence this is
likely to occur by direct passage through the cellular mem-
brane. The intracellular SUMO-1-peptide fusion is mostly
nuclear, probably as consequence of the nucleic acid
binding properties of the Tat PTD but also possibly due to
the SUMO-1 domain. Indeed, it has been reported for sev-
eral proteins that SUMO-1 addition triggers nuclear entry.
This indicates that our system is probably appropriate for
targeting nuclear proteins but not cytoplasmic factors. In
the nucleus the SHPs show a diffuse localization. These
observations are in agreement with the biological effect of
SHPR142 and SHPR190 which are able to block replica-
tion of HIV-1 in primary lymphocytes or macrophages
when added to the culture medium [14]. The results of the
fractionation experiments also support the previous con-
clusion that the ubiquitin GFP proteins are unable to pen-
etrate within the intracellular milieu. This is in agreement
with a previously published report that similar ubiquitin-
peptide and ubiquitin-protein constructs are not able to
enter the cytosol [29]. However, these authors interest-
ingly showed that dendritic cells were able to uptake and
process such hybrid proteins, at least to some extent.
Hence, in future studies it will be interesting to test if our
ubiquitin or SUMO-1 hybrids can be processed in such
cells. An intriguing aspect of our observations is the role
of the diglycine motif. Indeed, its presence seems to have
a strong negative effect on detection of the SUMO-1-pep-
tide hybrid in cells. As the presence of ubiquitin proteases
in the cellular membrane has been reported, it is possible
that cleavage after the C-terminal diglycine motif occur
simultaneously to crossing of the membrane. However,
we did not observe cleavage products of our hybrid pro-
Nuclear entry of SHPR 190 is energy-independent Figure 6
Nuclear entry of SHPR 190 is energy-independent.(a) 
Jurkat cells were cultured either in RPMI 1640 plus FCS at 
37°C (lane 1) or 4°C (lane 2), or in HBS buffer containing 10 
mM glucose (ctl, lane 3) or 10 mM deoxyglucose plus 1 µM 
rotenone (rot, lane 4) or 10 mM glucose plus 5 mM amilo-
ride (ami, lane 5) for 30 min. Cells were then incubated with 
2 µM of SHPR190 for 2 h, washed in HBS and lysed in RIPA 
buffer. Cell extracts were analysed by immunoblot using a 
monoclonal antibody to SUMO-1 (top panel) and to β-actin 
(bottom panel). (b) and (c) Jurkat cells were incubated for 2 
h either with 4 µM of FP1UG or with 2 µM of SHPR190 in 
HBS buffer at 37°C. Cells were then washed with HBS and 
fractionated into cytoplasmic (c, lane 1) nuclear (n, lane 2), 
and membrane fractions (m, lane 3). Samples of each fraction 
were analysed by immunoblot using anti-GFP (B) or anti 
SUMO-1 (C) antibodies (top panels). Cell fractionation was 
controlled by immunoblot using anti-RRM2 (ribonucleotide 
reductase peptide M2) antibody (bottom panels). (d) Jurkat 
cells were cultured in HBS buffer either at 37°C (lanes 1 to 
3) or 4°C (lanes 4 to 6), or in the presence of 5 mM amilo-
ride (lanes 7 to 9) 30 min before addition of 2 µM of 
SHPR190. 2 h after incubation, cells were washed in HBS and 
fractionated into cytoplasmic (m), nuclear (n), and membrane 
fractions (m). Samples from each fraction were analysed by 
immunoblot using the monoclonal antibody to SUMO-1.BMC Biotechnology 2008, 8:24 http://www.biomedcentral.com/1472-6750/8/24
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teins, even under conditions of proteasome activity block-
age [30,31]. It remains possible that after cleavage both
parts are routed towards endosomes and further degraded
in lysosomes. Structural studies have established the
importance of the diglycine motif in the interaction of
SUMO-1 or ubiquitin with C-terminal hydrolases or iso-
peptidase [32]. Hence, an expected effect of the mutation
of this sequence to alanine-arginine is loss of interaction
with these enzymes. It is possible that this event explains
the efficient capacity of the SHP proteins to enter cells.
Conclusion
The results presented in this report clarify the mechanism
of the cellular entry of SUMO-1-peptide-PTD constructs
and confirm that these constructs can efficiently deliver a
peptide into cells. Unexpectedly, they show that it is
important to block the cleavage that normally occurs at
the junction of SUMO-1 and the peptide by mutating the
diglycine motif. These constructs which can be easily pro-
duced in bacteria potentially offer an interesting means of
delivering a peptide able to act as an agonist or antagonist
with respect to a pivotal cellular protein.
Methods
Constructs
As a first step both 5'-CATGGGCGATTATAAAGATGAC-
GATAAAGGCGGTCA-3' and 5'-TATGACCGCCTT-
TATCGTCATCTTTATAATCGCC-3' oligonucleotides were
annealed and inserted between the Nco I and Nde I
restriction sites of vector pET15b giving vector pET-FLAG.
The ubiquitin coding sequence was amplified using the
following sense and antisense primers: 5'-
GAAGATCTCATATGGGCGGTACCCAAATCTTCGT-
GAAAACCC-3', 5'-GAAGATCTGCGGCCGCCCGGGATC-
CATACCACCTCTCAGACGC-3'. The amplified DNA
fragment was digested by the Nde I and BamH I restriction
enzymes and inserted between Nde I and BamH I restric-
tion sites of pET-FLAG, generating vector pET-FU. The GFP
coding sequence was obtained from vector pEGFP-1
(Clontech) by Not I – BamH I digestion and was inserted
between the Not I and BamH I restriction sites of vector
pET-FUG. The various PTDs were included in pET-FUG by
annealing appropriate oligonucleotides and inserting
them between the NdeI and KpnI restriction sites of pET-
FUG, giving vectors pET-FPUG. In some of these latter vec-
tors the sequence encoding ubiquitin was replaced by that
of SUMO-1 by digesting pET-FPUG by Kpn I and BamH I.
The SUMO-I sequence was obtained by PCR amplification
and inserted between these two restriction sites, giving
vectors pET-FPSG. Replacement of the GFP coding
sequence by that of the HA epitope was made by digesting
vectors pET-FPUG and pET-FPSG by BamH I and Not I
and inserting annealed sense and antisense following oli-
gonucleotides: 5'-GATCCTGTCTACCCATACGACGTC-
CCAGACTACGCTGGTAAGTAAGC-3'; 5'-
GGCCGCTTACTTACCAGCGTAGTCTGGGACGTCGTAT-
GGGTAGACAG-3'.
Protein production in bacteria
BL21(DE3)codon+ E. coli were transformed with plas-
mids encoding the different fusion proteins. Transform-
ants were selected on LB plates containing ampicillin and
colonies were then grown overnight at 37°C in LB broth
supplemented with 100 mg/ml ampicillin with shaking at
250 rpm. The overnight culture was diluted 25-fold with
fresh LB medium complemented with ampicillin and cul-
tured at 37°C until an OD at 600 nm of 0.9 was reached.
Protein expression was then induced by addition of 1 mM
IPTG (isopropyl-1-thio-β-D-galactopyranoside, Uptima)
and incubation at 24°C for 3 h. Bacteria were collected by
centrifugation and lysed by sonication in a buffer contain-
ing 20 mM NaCl, 0.1 M Tris-HCl pH 7.4, 10 mM MgCl2,
lysozyme, endonuclease and antiprotease agents (Com-
plete, Roche). After removal of cell debris by centrifuga-
tion, the extract was dialysed in TBS (20 mM Tris pH 7.6,
137 mM NaCl,) and loaded onto a M2 Anti-FLAG column
(anti-FLAG M2 Affinity Gel, Sigma). The column was
washed first with TBS supplemented with 200 mM NaCl
and then with TBS. The fusion proteins were eluted by
competition with 100 µg/ml of FLAG peptide diluted in
TBS, followed by washing with TBS. The fusion protein
fractions were then combined and dialysed in PBS (Phos-
phate-Buffered-Saline) supplemented with 0.5 mM β-
mercaptoethanol. Following dialysis, proteins were steri-
lized by filtration through a 0.025 µm membrane. All
purified fusion proteins were dissolved in PBS containing
0.5 mM β-mercaptoethanol then aliquoted and stored at -
80°C. Fusion protein purity was checked by 12% SDS-
PAGE followed by staining with Coomassie Brilliant Blue.
Protein concentrations were determined by densitometry
analysis using bovine serum albumin (BSA) as the stand-
ard ("Bradford test", Biorad).
Cell culture
Cells were incubated at 37°C in a 5% CO2-humidified
atmosphere. HeLa cells were cultured in Dulbecco's mod-
ified Eagle's medium and Jurkat cells in RPMI 1640
medium supplemented with 5 and 10% foetal calf serum,
respectively. Human peripheral blood mononuclear cells
(PBMC) were isolated from the blood of healthy donors
using Ficoll density gradients. Activation of the lym-
phocytes was performed by incubating the cells with 1
mg/ml phytohemagglutinin (PHA) and 20 IU/ml IL-2 for
48 h.
Immunoblot and immunofluorescence
For immunoblot analysis, the samples were loaded onto a
12% SDS-PAGE and proteins were electrotransferred on a
PVDF membrane (Amersham), which was then blocked
with PBS Tween 0.1% supplemented with 5% dry milk.BMC Biotechnology 2008, 8:24 http://www.biomedcentral.com/1472-6750/8/24
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Membranes were probed with either mouse monoclonal
anti-FLAG M2 antibody (Sigma, dilution 1:1000 in PBS
Tween 0.1%), a mouse monoclonal anti-GFP antibody
(dilution 1:1000 in PBS Tween 0.1%) or a mouse mono-
clonal anti-SUMO-1 antibody (Zymed, dilution 1:2000 in
PBS Tween 0.1%). Mouse anti-β actin (Sigma, dilution
1:5000) and rabbit polyclonal anti-RRM2 antibody were
also used to verify the extracts homogeneity or fractiona-
tion purity, respectively. Sheep anti-mouse or anti-rabbit
immunoglobulins coupled to peroxidase (Amersham,
dilution 1:6000) were used as secondary antibodies. Rev-
elation was performed by chemiluminescence using the
ECL or ECL plus reagent (Amersham Biosciences). Alter-
natively (Figure 2d and 2e), the membrane was incubated
with anti-mouse immunoglobulins coupled to cyanin 5
(dilution 1:500), and the signal visualized using a STORM
860 apparatus.
For immunofluorescence, cells treated with the different
fusion proteins were washed 3 times with PBS and then
placed in HBS culture medium (10 mM Hepes, pH 7.3; 10
mM D-glucose; 135 mM NaCl; 5 mM KCl; 2 mM MgCl2;
2 mM CaCl2). The cells were then directly loaded onto
glass slides coated with 1 mg/ml polylysin by incubation
during 5 min followed by a wash with H2O. When GFP
fusion proteins were used in the experiment, cells were
directly observed for GFP fluorescence by confocal micro-
scopy. Alternatively, SHP proteins, which do not include
GFP, were coupled to the Alexa Fluor 488 dye using the
Molecular Probes protein labelling kit (A-10235) accord-
ing to the manufacturer's instructions.
Abbreviations
GFP: green fluorescent protein; HBS: hepes buffer saline;
HIV-1: human immunodeficiency virus type 1; polyR:
polyarginine; PTD: protein transduction domain; RIPA:
radioimmunoprecipitation assay; SUMO: small ubiqui-
tin-related modifier; SHP: SUMO-1 heptapeptide PTD;
SHPR: SUMO-1 heptapeptide PTD Rev; SHPT: SUMO-1
heptapeptide PTD Tat; SDS : sodium dodecyl sulfate; Ub:
ubiquitin.
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